Calibrate vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health company delivering one-year GLP-1 programs with semaglutide or tirzepatide plus behavioral coaching, nutrition, and activity guidance via physician-supervised telehealth.
About
Calibrate is a metabolic health company that delivers a one-year weight loss program combining GLP-1 receptor agonist medications — including semaglutide and tirzepatide — with behavioral coaching, food education, sleep guidance, and activity programming through a telehealth platform. The program's clinical foundation differentiates it from consumer weight loss apps and traditional diet programs by centering medication management under physician supervision as the primary intervention, with lifestyle coaching structured to support long-term habit change alongside pharmaceutical treatment. Calibrate's approach reflects the clinical consensus that obesity is a chronic metabolic disease requiring medical treatment rather than a lifestyle choice addressable through willpower alone.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.